Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial

Effective immunosuppression is necessary for steroid‐resistant nephrotic syndrome (SRPNS) treatment, but intravenous cyclophosphamide (CY) may impose treatment‐related burdens. In this multicenter, open‐label, randomized non‐inferiority trial, the efficacy and safety of oral mizoribine (MZR) was evaluated among SRPNS patients in China and compared with those of intravenous CY. A total of 239 patients with persistent proteinuria despite adequate steroid therapy were randomized 1:1 to receive MZR or CY in combination with standardized steroid‐tapering therapy. The primary endpoint was the total remission (TR) rate, defined as complete or partial remission, at Week 52. The TR rates were 50.9% and 51.9% in the MZR and CY groups, respectively. Statistical analysis returned a relative risk ratio of 0.981 (95% confidence interval: 0.756–1.274), with a lower confidence limit exceeding the prespecified non‐inferiority margin of 0.674, demonstrating the non‐inferiority of MZR to CY. Treatment‐emergent adverse events occurred in 84.3% and 85.0% of patients in the MZR and CY groups, respectively. Oral MZR demonstrated non‐inferior efficacy and a safety profile comparable to intravenous CY. These findings support MZR as a practical therapeutic alternative that may expand treatment options for Chinese patients with SRPNS, particularly those requiring long‐term disease management and ongoing immunosuppression. Trial Registration : ClinicalTrials.gov Identifier: NCT02257697 https://clinicaltrials.gov/study/NCT02257697?term=NCT02257697&rank=1 .

Authors

Institutions

Publication Details

Journal
MedComm
Published
2026-11-20
DOI
https://doi.org/10.1002/mco2.71156
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial

Seika Yamaguchi, Guangyan Cai, Hua Wang, Luo Ping et al.
MedComm
Renal Diseases and Glomerulopathies
article

Similar Efficacy and Safety of Mizoribine Versus Cyclophosphamide in Patients With Steroid‐Resistant Nephrotic Syndrome: A Multicenter Randomized Non‐Inferiority Trial

Seika Yamaguchi, Guangyan Cai, Hua Wang, Luo Ping, 余月明, Jianxin Wan, 郑红光, Ying Li, Rong Wang, Aiping Yin, Gengru Jiang, Zhaohui Ni, Xueqing Yu, Yani He, Xinzhou Zhang, Li Zhang, Lihua Wang, Shumei Shi, Xiangmei Chen, Zheyi Dong, Wenhu Liu, Yan Xu, Xinling Liang, Zhonggao Xu, Hongli Lin, Wenge Li, Gang Xu
article en

Abstract

Effective immunosuppression is necessary for steroid‐resistant nephrotic syndrome (SRPNS) treatment, but intravenous cyclophosphamide (CY) may impose treatment‐related burdens. In this multicenter, open‐label, randomized non‐inferiority trial, the efficacy and safety of oral mizoribine (MZR) was evaluated among SRPNS patients in China and compared with those of intravenous CY. A total of 239 patients with persistent proteinuria despite adequate steroid therapy were randomized 1:1 to receive MZR or CY in combination with standardized steroid‐tapering therapy. The primary endpoint was the total remission (TR) rate, defined as complete or partial remission, at Week 52. The TR rates were 50.9% and 51.9% in the MZR and CY groups, respectively. Statistical analysis returned a relative risk ratio of 0.981 (95% confidence interval: 0.756–1.274), with a lower confidence limit exceeding the prespecified non‐inferiority margin of 0.674, demonstrating the non‐inferiority of MZR to CY. Treatment‐emergent adverse events occurred in 84.3% and 85.0% of patients in the MZR and CY groups, respectively. Oral MZR demonstrated non‐inferior efficacy and a safety profile comparable to intravenous CY. These findings support MZR as a practical therapeutic alternative that may expand treatment options for Chinese patients with SRPNS, particularly those requiring long‐term disease management and ongoing immunosuppression. Trial Registration : ClinicalTrials.gov Identifier: NCT02257697 https://clinicaltrials.gov/study/NCT02257697?term=NCT02257697&rank=1 .

MedCommVol. 7(12)
Hebei Medical University (CN), Fujian Medical University (CN), Army Medical University (CN), Sun Yat-sen University (CN), Asahi Kasei (Germany) (DE), Shanxi Medical University (CN), Capital Medical University (CN), Jilin University (CN), Guangdong General Hospital (CN), Renji Hospital (CN), China-Japan Friendship Hospital (CN), XinHua Hospital (CN), Chinese PLA General Hospital (CN), Third Hospital of Hebei Medical University (CN), Asahi Kasei (Japan) (JP), People's Liberation Army 401 Hospital (CN), ShenZhen People’s Hospital (CN), Shandong Provincial Hospital (CN), Affiliated Hospital of Qingdao University (CN), First Affiliated Hospital of Fujian Medical University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), General Hospital of Shenyang Military Region (CN), Second Hospital of Shanxi Medical University (CN), First Affiliated Hospital of Dalian Medical University (CN), Second Affiliated Hospital of Jilin University (CN), Beijing Friendship Hospital (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon